-
★
B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab
(Hinzugefügt: 30.12.2021 um 16:39 Uhr)
https://biblioteca.concytec.gob.pe/covid-19/b-cell-numbers-predict-humoral-and-cellular-response-upon-sars-cov-2-vaccination-among-patients-treated-with-rituximab/
-
★
Immunsuppressivum Rituximab erhöht Sterberisiko bei COVID-19 deutlich
(Hinzugefügt: 19.11.2021 um 15:28 Uhr)
https://www.aerzteblatt.de/nachrichten/129205/Immunsuppressivum-Rituximab-erhoeht-Sterberisiko-bei-COVID-19-deutlich
-
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
(Hinzugefügt: 13.06.2022 um 09:35 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(22)00098-4/fulltext
-
Rituximab Might Be Only Immunosuppressive Raising Mortality Risk in COVID-19
(Hinzugefügt: 22.03.2022 um 12:06 Uhr)
https://www.uspharmacist.com/article/rituximab-might-be-only-immunosuppressive-raising-mortality-risk-in-covid19
-
T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients
(Hinzugefügt: 22.03.2022 um 12:05 Uhr)
https://www.sciencedirect.com/science/article/pii/S0953620522000425#!
-
Some Patients on Rituximab Fail to Mount Robust T-cell Response to COVID-19 Vaccine
(Hinzugefügt: 22.03.2022 um 12:04 Uhr)
https://ancavasculitisnews.com/2022/02/16/older-aav-patients-low-t-cell-count-rituximab-greater-risk-after-covid-vaccination-study/
-
Case Report: Unremitting COVID-19 Pneumonia, Viral Shedding, and Failure to Develop Anti-SARS-CoV-2 Antibodies for More Than 6 Months in Patient with Mantle Cell Lymphoma Treated with Rituximab
(Hinzugefügt: 06.03.2022 um 20:30 Uhr)
https://www.ajtmh.org/view/journals/tpmd/aop/article-10.4269-ajtmh.21-1010/article-10.4269-ajtmh.21-1010.xml
-
Breakthrough SARS-CoV-2 infections in immune mediated disease patients undergoing B cell depleting therapy
(Hinzugefügt: 06.03.2022 um 18:33 Uhr)
https://www.medrxiv.org/content/10.1101/2022.02.21.22271289v1
-
Outcomes for Hospitalized COVID-19 Patients Taking Immunosuppressive Medications Similar to Non-Immunosuppressed Patients (Ausnahme: Rituximab)
(Hinzugefügt: 10.01.2022 um 12:51 Uhr)
https://publichealth.jhu.edu/2021/outcomes-for-hospitalized-covid-19-patients-taking-immunosuppressive-medications-similar-to-non-immunosuppressed-patients
-
Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab
(Hinzugefügt: 29.12.2021 um 17:51 Uhr)
https://pubmed.ncbi.nlm.nih.gov/34862310/
-
Prolonged incubation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a patient on rituximab therapy
(Hinzugefügt: 29.12.2021 um 17:51 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33023685/
-
Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients
(Hinzugefügt: 29.12.2021 um 15:54 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00418-5/fulltext
-
Immunsuppressivum Rituximab erhöht Sterberisiko bei COVID-19 deutlich
(Hinzugefügt: 18.12.2021 um 15:06 Uhr)
https://www.aerzteblatt.de/nachrichten/129205/Immunsuppressivum-Rituximab-erhoeht-Sterberisiko-bei-COVID-19-deutlich
-
Rituximab likely raises risk of hospital death in COVID-19 patients
(Hinzugefügt: 18.12.2021 um 15:05 Uhr)
https://www.mdedge.com/rheumatology/article/249393/rheumatoid-arthritis/rituximab-likely-raises-risk-hospital-death-covid
-
Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study
(Hinzugefügt: 18.12.2021 um 15:04 Uhr)
https://rmdopen.bmj.com/content/7/3/e001925
-
Timing of rituximab infusion not tied to risk for COVID-19 hospitalization
(Hinzugefügt: 18.12.2021 um 15:03 Uhr)
https://www.healio.com/news/neurology/20211206/timing-of-rituximab-infusion-not-tied-to-risk-for-covid19-hospitalization
-
Only rituximab, not other immunosuppressants, associated with poor COVID-19 outcomes
(Hinzugefügt: 18.12.2021 um 15:02 Uhr)
https://rheumatology.medicinematters.com/covid-19/rituximab/national-covid-cohort-collaborative/19947862
-
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative
(Hinzugefügt: 09.12.2021 um 16:52 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00325-8/fulltext
-
Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
(Hinzugefügt: 07.12.2021 um 19:36 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2786701
-
COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma
(Hinzugefügt: 06.12.2021 um 13:39 Uhr)
https://journals.lww.com/hemasphere/fulltext/2021/07000/covid_19_in_patients_receiving_cd20_depleting.15.aspx
-
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
(Hinzugefügt: 04.12.2021 um 18:53 Uhr)
https://pubmed.ncbi.nlm.nih.gov/34049860/
-
Covid-19-vaccine/rituximab
(Hinzugefügt: 19.11.2021 um 16:51 Uhr)
https://link.springer.com/article/10.1007/s40278-021-04598-4
-
COVİD‑19 infection inamembranous nephropathy patient treated withrituximab
(Hinzugefügt: 19.11.2021 um 16:49 Uhr)
https://www.researchgate.net/publication/344123802_COVID-19_infection_in_a_membranous_nephropathy_patient_treated_with_rituximab
-
B-Cell depletion with rituximab in the COVID-19 pandemic: where do we stand?
(Hinzugefügt: 19.11.2021 um 16:47 Uhr)
https://discovery.ucl.ac.uk/id/eprint/10111882/9/Chambers_RTX%20COVID--160720%20-%20CLEAN%20HBr.pdf
-
B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?
(Hinzugefügt: 19.11.2021 um 16:46 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33521659/
-
COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge
(Hinzugefügt: 19.11.2021 um 16:05 Uhr)
https://www.frontiersin.org/articles/10.3389/fimmu.2021.763412/full
-
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative
(Hinzugefügt: 19.11.2021 um 15:25 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00325-8/fulltext
-
Rituximab, ocrelizumab pose risks in patients with MS and COVID-19
(Hinzugefügt: 25.10.2021 um 07:25 Uhr)
https://www.healio.com/news/neurology/20211007/rituximab-ocrelizumab-pose-risks-in-patients-with-ms-and-covid19
-
Kasus: Patientin war über 11 Monate mit SARS-CoV-2 infiziert
(Hinzugefügt: 22.10.2021 um 16:19 Uhr)
https://www.aerzteblatt.de/nachrichten/128340/Kasus-Patientin-war-ueber-11-Monate-mit-SARS-CoV-2-infiziert
-
Impact of rituximab on COVID-19 outcomes
(Hinzugefügt: 03.10.2021 um 08:10 Uhr)
https://pubmed.ncbi.nlm.nih.gov/34549309/
-
Rituximab und COVID-19: Kommt es auf das Timing an?
(Hinzugefügt: 20.09.2021 um 09:21 Uhr)
https://link.springer.com/article/10.1007/s15002-021-3260-0
-
Patients With MS on Rituximab at Higher Risk for COVID-19 Hospitalization
(Hinzugefügt: 20.09.2021 um 09:21 Uhr)
https://www.neurologylive.com/view/patients-ms-rituximab-higher-risk-covid-19-hospitalization
-
MS Wrap-up: Rituximab and COVID-19 Risk, New App for Functional Impairment, and More
(Hinzugefügt: 20.09.2021 um 09:20 Uhr)
https://www.ajmc.com/view/ms-wrap-up-rituximab-and-covid-19-risk-new-app-for-functional-impairment-and-more
-
Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD
(Hinzugefügt: 20.09.2021 um 09:19 Uhr)
https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-021-02218-4
-
Rituximab a Hazard in RA Patients With COVID
(Hinzugefügt: 20.09.2021 um 09:19 Uhr)
https://www.medpagetoday.com/meetingcoverage/eular/92897
-
Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed
(Hinzugefügt: 14.09.2021 um 07:25 Uhr)
https://pubmed.ncbi.nlm.nih.gov/34409510/
-
Rheumatologie: Glukokortikoide und Rituximab führen zu einem schweren COVID-19-Verlauf
(Hinzugefügt: 03.08.2021 um 09:22 Uhr)
https://dgn.org/neuronews/journal_club/rheumatologie-glukokortikoide-und-rituximab-fuehren-zu-einem-schweren-covid-19-verlauf/
-
Rituximab und COVID-19: Kommt es auf das Timing an?
(Hinzugefügt: 03.08.2021 um 09:21 Uhr)
https://link.springer.com/article/10.1007/s15002-021-3260-0
-
Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD
(Hinzugefügt: 03.08.2021 um 09:21 Uhr)
https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-021-02218-4
-
COVID-19: Prognose für ERE-Patienten offenbar doch schlechter als für Infizierte aus der Allgemeinbevölkerung
(Hinzugefügt: 03.08.2021 um 09:20 Uhr)
https://www.rheumaguide.de/content/covid-19-prognose-fur-ere-patienten-offenbar-doch-schlechter-als-fur-infizierte-aus-der-0
-
Between a rock and a hard place: COVID-19 vaccination and patients on rituximab therapy
(Hinzugefügt: 03.08.2021 um 09:14 Uhr)
https://www.tandfonline.com/doi/figure/10.1080/10428194.2021.1957879?scroll=top&needAccess=true
-
Antikörper gegen CD 20: ein Risiko in der Pandemie?
(Hinzugefügt: 06.04.2021 um 07:26 Uhr)
https://link.springer.com/article/10.1007/s15005-020-1512-1
-
Autoimmune disease, rituximab linked to higher risk for severe COVID-19 pneumonia
(Hinzugefügt: 06.04.2021 um 07:25 Uhr)
https://www.healio.com/news/rheumatology/20210330/autoimmune-disease-rituximab-linked-to-higher-risk-for-severe-covid19-pneumonia
-
B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?
(Hinzugefügt: 06.04.2021 um 07:25 Uhr)
https://www.researchgate.net/publication/343353180_B-cell_depletion_with_rituximab_in_the_COVID-19_pandemic_where_do_we_stand
-
Effect of Rituximab Timing on COVID-19-Related Death in Patients With ANCA-Associated Vasculitis
(Hinzugefügt: 06.04.2021 um 07:24 Uhr)
https://www.rheumatologyadvisor.com/home/topics/vasculitis/rituximab-timing-immunoglobulins-covid19-death-in-anca-vasculitis/
-
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19
(Hinzugefügt: 06.04.2021 um 07:21 Uhr)
https://ashpublications.org/blood/article/136/20/2290/463806/Convalescent-plasma-therapy-for-B-cell-depleted
-
Rituximab use may be a risk factor for severe COVID-19
(Hinzugefügt: 06.04.2021 um 07:20 Uhr)
https://rheumatology.medicinematters.com/covid-19/rituximab/rituximab-use-may-be-a-risk-factor-for-severe-covid-19/19018900
-
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
(Hinzugefügt: 06.04.2021 um 07:18 Uhr)
https://www.sciencedirect.com/science/article/abs/pii/S0959804920303506
-
Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis
(Hinzugefügt: 06.04.2021 um 07:17 Uhr)
https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keab175/6145568
-
Rheumatologie: Glukokortikoide und Rituximab führen zu einem schweren COVID-19-Verlauf
(Hinzugefügt: 06.04.2021 um 07:16 Uhr)
https://dgn.org/neuronews/journal_club/rheumatologie-glukokortikoide-und-rituximab-fuehren-zu-einem-schweren-covid-19-verlauf/